

# CITATION REPORT

List of articles citing

## Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease

DOI: 10.1681/asn.2016121372

Journal of the American Society of Nephrology: JASN,  
2017, 28, 2263-2274.

**Source:** <https://exaly.com/paper-pdf/66298823/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 53 | Clinical assessment and treatment of diabetes in patients with chronic kidney disease. <i>Revista Clinica Espanola</i> , <b>2018</b> , 218, 305-315  | 0.7  | 1         |
| 52 | Metabolomics-based evidence of the hypoglycemic effect of Ge-Gen-Jiao-Tai-Wan in type 2 diabetic rats via UHPLC-QTOF/MS analysis. <i>Journal of Ethnopharmacology</i> , <b>2018</b> , 219, 299-318   | 5    | 41        |
| 51 | 8. Pharmacologic Approaches to Glycemic Treatment:. <i>Diabetes Care</i> , <b>2018</b> , 41, S73-S85   | 14.6 | 551       |
| 50 | The ABCs of chronic kidney disease. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , <b>2018</b> , 31, 17-25   | 0.8  | 2         |
| 49 | SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. <i>JCI Insight</i> , <b>2018</b> , 3,   | 9.9  | 57        |
| 48 | The Role of Deprescribing in Older Adults with Chronic Kidney Disease. <i>Drugs and Aging</i> , <b>2018</b> , 35, 973-984  | 14   | 21        |
| 47 | Long-term prospective observation suggests that glomerular hyperfiltration is associated with rapid decline in renal filtration function: A multiethnic study. <i>Diabetes and Vascular Disease Research</i> , <b>2018</b> , 15, 417-423   | 3.3  | 10        |
| 46 | Clinical assessment and treatment of diabetes in patients with chronic kidney disease. <i>Revista Clinica Espanola</i> , <b>2018</b> , 218, 305-315  | 0.5  | 0         |
| 45 | Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). <i>Toxins</i> , <b>2018</b> , 10,   | 4.9  | 19        |
| 44 | Managing the Diabetic Kidney Patient. <i>Journal for Nurse Practitioners</i> , <b>2018</b> , 14, 526-530   | 0.6  |           |
| 43 | SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 72, 267-277   | 7.4  | 60        |
| 42 | Clinical pharmacology of glucagon-like peptide-1 receptor agonists. <i>Hormones</i> , <b>2018</b> , 17, 333-350  | 3.1  | 26        |
| 41 | Why Do Patients With Well-Controlled Vascular Risk Factors Develop Progressive Chronic Kidney Disease?. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 1170-1180  | 3.8  | 3         |
| 40 | Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing. <i>CKJ: Clinical Kidney Journal</i> , <b>2019</b> , 12, 620-628   | 4.5  | 8         |
| 39 | Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2019</b> , 29, 1127-1150 | 4.5  | 38        |
| 38 | Effect of Bilastine on Diabetic Nephropathy in DBA2/J Mice. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,   | 6.3  | 1         |
| 37 | Astragalus membranaceus and Panax notoginseng, the Novel Renoprotective Compound, Synergistically Protect against Podocyte Injury in Streptozotocin-Induced Diabetic Rats. <i>Journal of Diabetes Research</i> , <b>2019</b> , 2019, 1602892   | 3.9  | 10        |

|    |   |     |     |
|----|---|-----|-----|
| 36 | Preventing and treating kidney disease in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 277-294   | 4   | 23  |
| 35 | Improving Drug Use and Dosing in Chronic Kidney Disease. <b>2019</b> , 250-272.e5   |     |     |
| 34 | Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , <b>2019</b> , 45, 110-121   | 5.4 | 31  |
| 33 | The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. <i>Journal of Pharmacological Sciences</i> , <b>2019</b> , 139, 37-41  | 3.7 | 2   |
| 32 | Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". <i>Journal of Nephrology</i> , <b>2020</b> , 33, 9-35 | 4.8 | 38  |
| 31 | Dynamic hyperpolarized C MR spectroscopic imaging using SPICE in mouse kidney at 9.4 T. <i>NMR in Biomedicine</i> , <b>2020</b> , 33, e4230   | 4.4 | 3   |
| 30 | KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , <b>2020</b> , 98, S1-S115   | 9.9 | 251 |
| 29 | Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents. <i>International Journal of Clinical Practice</i> , <b>2020</b> , 74, e13586  | 2.9 | 0   |
| 28 | Ten things to know about ten cardiovascular disease risk factors ("ASPC Top Ten - 2020"). <i>American Journal of Preventive Cardiology</i> , <b>2020</b> , 1, 100003  | 1.9 | 3   |
| 27 | Noninsulin Therapy for Diabetes. <i>Physician Assistant Clinics</i> , <b>2020</b> , 5, 153-165  | 0.2 |     |
| 26 | Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,   | 5.1 | 17  |
| 25 | VEGFR2 Blockade Improves Renal Damage in an Experimental Model of Type 2 Diabetic Nephropathy. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,   | 5.1 | 11  |
| 24 | Clinical characteristics and outcomes of patients with end-stage renal disease hospitalized with diabetes ketoacidosis. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,   | 4.5 | 6   |
| 23 | Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 1225-1234   | 5.6 | 3   |
| 22 | A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 34, 428-437   | 1.3 | 5   |
| 21 | Ten things to know about ten cardiovascular disease risk factors. <i>American Journal of Preventive Cardiology</i> , <b>2021</b> , 5, 100149  | 1.9 | 19  |
| 20 | Mesenchymal Stem Cells: An Overview of Their Potential in Cell-Based Therapy for Diabetic Nephropathy. <i>Stem Cells International</i> , <b>2021</b> , 2021, 6620811  | 5   | 3   |
| 19 | EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , <b>2021</b> , 6-61  | 0.7 | 2   |

|    |   |      |    |
|----|---|------|----|
| 18 | Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. <i>BioMed Research International</i> , <b>2021</b> , 2021, 1497449  | 3    | 39 |
| 17 | Characterization of Enlarged Kidneys and Their Potential for Inducing Diabetes in DEK Rats. <i>Biology</i> , <b>2021</b> , 10,  | 4.9  | 1  |
| 16 | Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study. <i>Diabetes Care</i> , <b>2021</b> ,   | 14.6 | 6  |
| 15 | Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. <i>Acta Pharmaceutica Sinica B</i> , <b>2021</b> , 11, 2749-2767   | 15.5 | 19 |
| 14 | The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 679-695  | 3.6  | 0  |
| 13 | Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center. <i>Journal of Clinical Medicine Research</i> , <b>2019</b> , 11, 267-274 | 2.9  | 13 |
| 12 | Effects of LncRNA MALAT1 on microangiopathy and diabetic kidney disease in diabetic rats by regulating ERK/MAPK signaling pathway. <i>Minerva Medica</i> , <b>2020</b> , 111, 184-186   | 2.2  | 5  |
| 11 | STORIA NATURALE DELLA MALATTIA RENALE NEL DIABETE E TRATTAMENTO DELL'IPERGLICEMIA NEI PAZIENTI CON DIABETE DI TIPO 2 E RIDOTTA FUNZIONE RENALE. <i>Il Diabete</i> , <b>2019</b> , 3,  | 0    |    |
| 10 | Mitochondria in Diabetic Kidney Disease. <i>Cells</i> , <b>2021</b> , 10,   | 7.9  | 4  |
| 9  | Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.. <i>Journal of Pathology</i> , <b>2022</b> ,   | 9.4  | 1  |
| 8  | DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 36, 108101  | 3.2  | 2  |
| 7  | Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 778776  | 5.6  | 1  |
| 6  | Ten things to know about ten cardiovascular disease risk factors - 2022.. <i>American Journal of Preventive Cardiology</i> , <b>2022</b> , 10, 100342   | 1.9  | 3  |
| 5  | Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease. <b>2022</b> , 27, 6221   |      | 1  |
| 4  | Use of Glucose-Lowering Agents in Diabetes and Chronic Kidney Disease. <b>2022</b> ,  |      | 0  |
| 3  | Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century. <b>2022</b> , 97, 1904-1919  |      | 0  |
| 2  | KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <b>2022</b> , 102, S1-S127  |      | 8  |
| 1  | Cardiovascular Disease and CKD. <b>2022</b> , 505-525   |      | 0  |

